To ATCC Valued Customers,

ATCC stands ready to support our customers’ needs during the coronavirus pandemic. If you experience any issues with your products or services, please contact ATCC Customer Service at sales@atcc.org. For Technical questions please contact tech@atcc.org. Thank you.
X

iPSC-derived CD34+ Cells, BXS0117 (ATCC® ACS-7020)

Organism: Homo sapiens, human  /  Tissue:

iPSC-derived CD34+ cells

 / 

Permits and Restrictions

View Permits View Restrictions

Organism Homo sapiens, human
Tissue

iPSC-derived CD34+ cells

Product Format frozen 1.0 mL
Morphology rounded
Culture Properties suspension
Biosafety Level 2

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Age 27
Gender female
Ethnicity Asian
Applications

Biopharma: Cancer immunology, drug development, toxicity screening, and blood lineage differentiation studies.

Storage Conditions liquid nitrogen vapor phase
Comments

Human iPSC-derived CD34+ can be used for drug development, toxicity screening, and cancer immunology experiments. There is reduced lot-to-lot variability in this cell line as they are all derived from the parental iPSC line (ATCC ACS-1031) .

Complete Growth Medium iPSC-derived CD34+ hematopoietic progenitor cells should be thawed prior to their intended use in application specific media. ATCC recommends thawing them in RPMI-1640 (ATCC 30-2001). ATCC does not recommend maintaining iPSC-derived CD34+ hematopoietic progenitor cells in culture in the absence of application-specific growth factors.
Cryopreservation N/A: As this cell line is intended to be consumable no sub culturing and no cryopreservation is recommended.
Culture Conditions
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37°C
Cells per Vial Approximately 3 x 106 cells
Volume 1.0 mL
STR Profile
Amelogenin: X
CSF1PO: 10 ,12
D13S17: 9 ,12
D16S539: 11
D5S818: 12
D7S820: 9 ,13
TH01: 7 ,9
TPOX: 8 ,11
vWA: 19
Sterility Tests Bacteria and yeast: No growth
Mycoplasma: No growth
Viral Testing Hepatitis B: None detected
Cytomegalovirus: None detected
Human immunodeficiency virus: None detected
Epstein-Barr virus: None detected
Human papillomavirus: None detected
Viability ≥ 80%
Name of Depositor ATCC
Year of Origin 2018
References

Espinoza JL, et al. Hematopoiesis by iPSC-derived hematopoietic stem cells of aplastic anemia that escape cytotoxic T-cell attack. Blood Adv 2(4): 390-400, 2018. PubMed: 30201698

Tan YT, et al. Respecifying human iPSC-derived blood cells to highly engraftable hematopoietic stem and progenitor cells with a single factor PNAS 9(115): 2180-2185, 2018. PubMed: 29386396

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Restrictions

This product may be used by investigator for research purposes subject to the Limited Use Label License and any additional third party terms. This product is subject to claims under U.S. Patent Nos. 8,058,065 and 8,048,999, pending patent applications, and foreign counterparts thereof.  In addition, this product was generated using the proprietary technology of the DNAVEC Corporation, including, without limitation, recombinant Sendai virus vectors. For information on obtaining additional rights, please contact licensing@atcc.org


References

Espinoza JL, et al. Hematopoiesis by iPSC-derived hematopoietic stem cells of aplastic anemia that escape cytotoxic T-cell attack. Blood Adv 2(4): 390-400, 2018. PubMed: 30201698

Tan YT, et al. Respecifying human iPSC-derived blood cells to highly engraftable hematopoietic stem and progenitor cells with a single factor PNAS 9(115): 2180-2185, 2018. PubMed: 29386396